// App-Quantinova.ai

559 : Outcomes after chemotherapy in early-stage breast cancer (EBC) patients who underwent a 21-gene expression assay.

Researchers

Presenter

  • Carlos Hernando Barcenas

Principal Investigators

  • Arup Kumar Sinha

  • Akshara Singareeka Raghavendra

  • Masood Pasha Syed

  • Limin Hsu

  • Modesto Patangan

  • Mariana Chavez-Mac Gregor

  • Yu Shen

  • Sharon Hermes Giordano

  • Naoto T. Ueno

  • Vicente Valero

  • Debu Tripathy

Medical Centers

  • Department of Breast Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA

  • Department of Health Services Research, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX

  • Department of Bioinformatics, The University of Texas MD Anderson Cancer Center, Houston, TX

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved